The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis

References

• Mu LM, Ju RJ, Liu R, et al. Dual-functional drug liposomes in treatment of resistant cancers. Adv Drug Deliv Rev. 2017;115:46–56.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009;115:3475–3482.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Biganzoli L, Canney P, et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–887.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res. 1997;3:373–379.
   PubMed Web of Science ®Google Scholar
• Hartwell JL. Plants used against cancer: a survey. Lawrence, MA: Quarterman; 1982.
   Google Scholar
• Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets. 2006;7:265–277.
   PubMed Web of Science ®Google Scholar
• Ghantous A, Sinjab A, Herceg Z, et al. Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 2013;18:894–905.
   PubMed Web of Science ®Google Scholar
• Yu HJ, Jung JY, Jeong JH, et al. Induction of apoptosis by parthenolide in human oral cancer cell lines and tumor xenografts. Oral Oncol. 2015;51:602–609.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang X, Sun J, et al. Parthenolide suppresses pancreatic cell growth by autophagy-mediated apoptosis. Onco Targets Ther. 2017;10:453–461.
   PubMed Web of Science ®Google Scholar
• Yang C, Yang QO, Kong QJ, et al. Parthenolide induces reactive oxygen species-mediated autophagic cell death in human osteosarcoma cells. Cell Physiol Biochem. 2016;40:146–154.
   PubMed Web of Science ®Google Scholar
• Zahedpanah M, Shaiegan M, Ghaffari SH, et al. Parthenolide induces apoptosis in committed progenitor AML cell line U937 via reduction in osteopontin. Rep Biochem Mol Biol. 2016;4:82–88.
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D'Anneo A, et al. The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells. J Cell Physiol. 2015;230:1276–1289.
   PubMed Web of Science ®Google Scholar
• Duan D, Zhang J, Yao J, et al. Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells. J Biol Chem. 2016;291:10021–10031.
   PubMed Web of Science ®Google Scholar
• Liu YC, Kim SL, Park YR, et al. Parthenolide promotes apoptotic cell death and inhibits the migration and invasion of SW620 cells. Intest Res. 2017;15:174–181.
   PubMed Web of Science ®Google Scholar
• Lin M, Bi H, Yan Y, et al. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget. 2017;8:23436–23447.
   PubMedGoogle Scholar
• Kim SL, Kim SH, Park YR, et al. Combined parthenolide and balsalazide have enhanced antitumor efficacy through blockade of NF-κB activation. Mol Cancer Res. 2017;15:141–151.
   PubMed Web of Science ®Google Scholar
• Jeyamohan S, Moorthy RK, Kannan MK, et al. Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer. Biotechnol Lett. 2016;38:1251–1260.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Zhang D, Yang DC. Biosynthesis and biotechnological production of ginsenosides. Biotechnol Adv. 2015;33:717–735.
   Google Scholar
• Kwak CW, Son YM, Gu MJ, et al. A bacterial metabolite, compound K, induces programmed necrosis in MCF-7 cells via GSK3β. J Microbiol Biotechnol. 2015;25:1170–1176.
   PubMed Web of Science ®Google Scholar
• Shin KO, Seo CH, Cho HH, et al. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells. Arch Pharm Res. 2014;37:1183–1192.
   PubMed Web of Science ®Google Scholar
• Kim AD, Kang KA, Kim HS, et al. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis. 2013;4:e750.
   PubMed Web of Science ®Google Scholar
• Zhang K, Li Y. Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer. Pharm Biol. 2016;54:561–568.
   PubMed Web of Science ®Google Scholar
• Igami K, Ozawa M, Inoue S, et al. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics. J Pharm Pharmacol. 2016;68:646–654.
   PubMed Web of Science ®Google Scholar
• Zhao AQ, Zhao JH, Zhang SQ, et al. Determination of parthenolide in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2016;119:99–103.
   PubMed Web of Science ®Google Scholar
• Wang W, Li M, Zhang Z, et al. Design, synthesis and evaluation of multi-functional tLyP-1-hyaluronic acid-paclitaxel conjugate endowed with broad anticancer scope. Carbohydr Polym. 2017;156:97–107.
   PubMed Web of Science ®Google Scholar
• Jiang D, Gao X, Kang T, et al. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer. Nanoscale. 2016;8:3100–3118.
   PubMed Web of Science ®Google Scholar
• Jin X, Yang Q, Zhang Y. Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer. Int J Nanomed. 2017;12:5109–5118.
   PubMed Web of Science ®Google Scholar
• Jin X, Li M, Yin L, et al. Tyroservatide-TPGS-paclitaxel liposomes: tyroservatide as a targeting ligand for improving breast cancer treatment. Nanomedicine. 2017;13:1105–1115.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Kogure K, Futaki S, et al. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem. 2006;281:3544e51.
   Web of Science ®Google Scholar
• Wu H, Liu S, Gong J, et al. A novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction. Cancer Lett. 2017;393:22–32.
   PubMed Web of Science ®Google Scholar
• Ulrich-Merzenich GS. Combination screening of synthetic drugs and plant derived natural product potential and challenges for drug development. Synergy. 2014;1:59–69.
   Google Scholar
• Rastegar R, Akbari Javar H, Khoobi M, et al. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer. Artif Cells Nanomed Biotechnol. 2018;24:1–10.
   Web of Science ®Google Scholar
• Pashaei-Asl F, Pashaei-Asl R, Khodadadi K, et al. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif Cells Nanomed Biotechnol. 2018;46:1483–1487.
   PubMed Web of Science ®Google Scholar
• Hemati M, Haghiralsadat F, Yazdian F, et al. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artif Cells Nanomed Biotechnol. 2018;22:1–17.
   Web of Science ®Google Scholar
• Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–1181.
   PubMedGoogle Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA. 2009;106:16157–16162.
   PubMed Web of Science ®Google Scholar